Key Points
- William Rote sold 9,100 shares of Travere on April 22 at an average price of $39.09 under a pre-arranged Rule 10b5-1 plan, generating $355,719 and reducing his stake by 7.39% to 113,987 shares (≈$4.46M).
- Travere shares opened at $40.82, trade in a 12‑month range of $13.88–$43.31, have a market cap of about $3.77B and negative PE, with 50‑ and 200‑day moving averages near $30.77 and $31.97 respectively.
- Analyst and institutional sentiment is generally positive: ten analysts rate the stock a Buy, consensus rating is " Moderate Buy" with a consensus target of $42.50, and major investors (Vanguard, State Street, Perceptive, Renaissance) have recently increased positions.
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider William Rote sold 9,100 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $39.09, for a total transaction of $355,719.00. Following the sale, the insider directly owned 113,987 shares in the company, valued at approximately $4,455,751.83. The trade was a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Travere Therapeutics Price Performance
Shares of Travere Therapeutics stock opened at $40.82 on Friday. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $43.31. The business has a 50-day moving average price of $30.77 and a 200 day moving average price of $31.97. The firm has a market cap of $3.77 billion, a PE ratio of -136.06 and a beta of 0.86.
Institutional Trading of Travere Therapeutics
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Travere Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock valued at $158,059,000 after purchasing an additional 619,085 shares during the last quarter. State Street Corp boosted its stake in Travere Therapeutics by 47.8% during the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock worth $181,752,000 after buying an additional 1,538,827 shares during the last quarter. Perceptive Advisors LLC grew its holdings in Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock valued at $163,469,000 after buying an additional 483,565 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Travere Therapeutics by 27.4% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock worth $41,203,000 after acquiring an additional 599,102 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Travere Therapeutics by 28.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock worth $85,849,000 after acquiring an additional 494,665 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on TVTX shares. JPMorgan Chase & Co. cut their price objective on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a research report on Wednesday, March 25th. Wedbush increased their target price on Travere Therapeutics from $39.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, April 14th. Piper Sandler raised shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price target on the stock in a research note on Tuesday, April 14th. Guggenheim upped their price objective on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, April 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Tuesday, April 14th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $42.50.
Check Out Our Latest Research Report on TVTX
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
